PRECIRIX is a private biotechnology company that designs and develops precision radiopharmaceuticals for cancer treatment. The company's lead program targets Fibroblast Activation Protein (FAP), with research on multiple isotopes and combination therapies ongoing.

PRECIRIX

CrUX Dataset

reCAPTCHA v2

CrUX Top 10m

Director Clinical Operations

Audrey Rossow

Information Technology

Dimitrios Mantzilas

Morten Graugaard Døssing

Simone Botti

Marten Steen

Ohad Hammer

Sabine Dandiguian

Nick Devoogdt

Karl Nagler

Jasper Bos

Matthias D'Huyvetter

Co Founder & Science Director

Ruth Devenyns

Jens De Vos

Operations Manager

Co-Founder

Geert Raes

IP & Legal Advisor & Co-founder

Belgium Companies With Less Than $500M in Revenue (Top 10K)

Europe Companies With Fewer Than 50 Employees (Top 10K)

Biotechnology Companies With Less Than $10M in Revenue (Top 10K)

Europe, Middle East, and Africa (EMEA) Early Stage Companies With Less Than $10M in Revenue

Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.

Forbion Capital Partners

Inkef

Jeito Capital

Series B - Precirix

Gimv

V-Bio Ventures

Series A - Precirix

Computer and Software Services and Scientific Services

Brussels

Brussels Hoofdstedelijk Gewest

Belgium

Europe

Precirix

Antibody fragment against fap

Reactions of radioactive compounds facilitated by a solid phase

Antibody fragment against folr1

Precirix enters into collaboration with Eckert & Ziegler for the development of its 68Ga-based compounds

Precirix strengthens patent portfolio of its precision radiopharmaceuticals platform

Belgian biotech company Precirix secures €80M from Amsterdam-based INKEF Capital, others

Precirix Raises €80M in Series B Funding

Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals

Precirix closes €80M series B with plans to complete phase II cancer trial

A single-domain antibody targeting HER2, combined with iodine-131, currently in Phase I/II clinical trials for HER2-positive metastatic breast, gastric, and gastroesophageal cancer.

A program targeting Fibroblast Activation Protein, transitioning into clinical trials, aimed at developing radiopharmaceuticals for cancer treatment.

A method that uses an imaging version of a product to select patients, followed by a therapeutic dose for treatment.

Philippines

Asia

United Kingdom

United States

North America

Brazil

South America

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 19, 2024 6:33 AM	d34a8220
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 6:33 AM	bfc629b4
crunchbase trigger	general	Nov 19, 2024 6:33 AM	4c61aade
crunchbase profile	general	Nov 20, 2024 12:29 AM	a5ed181c
li profile	general	Nov 19, 2024 6:33 AM	ae40b295
translate crunchbase fundingrounds	general	Nov 20, 2024 1:21 AM	66cfcc6e
peers	general	Nov 19, 2024 6:33 AM	4c1c9af3
news basic	general	Nov 19, 2024 6:33 AM	e00e1e45
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

PREC

COM:PRECIRIX

PRECIRIX